Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 31.91
-0.27 (-0.84%)
Aug 31, 2026, 3:04 PM CST
SHE:002294 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 4,701 | 4,353 | 4,012 | 3,365 | 3,482 | 3,058 |
Revenue Growth | 14.64% | 8.48% | 19.22% | -3.35% | 13.85% | 11.68% |
Gross Profit Gross Profit Growth | 3,488 | 3,248 | 2,874 | 2,300 | 2,481 | 2,247 |
Operating Income Operating Income Growth | 657.27 | 640.47 | 683.83 | 565.82 | 565.58 | 504.3 |
Net Income Net Income Growth | 673.52 | 651.5 | 601.57 | 580.07 | 637.09 | 533.73 |
Earnings Per Share EPS Growth | 0.60 | 0.58 | 0.54 | 0.52 | 0.58 | 0.50 |
EPS Growth | 7.13% | 7.41% | 3.85% | -10.35% | 16.00% | 733.33% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth | 4,300 | 3,973 | 3,707 | 3,150 | 3,382 | 3,000 |
Medical Devices Medical Devices Growth | 400.98 | 379.94 | 305.41 | 215.56 | 100.44 | 58.88 |
Total Total Growth | 4,701 | 4,353 | 4,012 | 3,365 | 3,482 | 3,058 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 2,308 | 3,091 | 2,848 | 2,204 | 3,530 | 3,296 |
Total Debt Total Debt Growth | 428.24 | 290.19 | 133.88 | 63.47 | 208.23 | 79.1 |
Net Cash (Debt) Net Cash Growth | 1,880 | 2,801 | 2,714 | 2,140 | 3,322 | 3,217 |
Net Cash Growth | -30.60% | 3.18% | 26.83% | -35.58% | 3.28% | 366.56% |
Net Cash Per Share Net Cash Per Share Growth | 1.67 | 2.49 | 2.44 | 1.92 | 3.02 | 3.01 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 1,093 | 1,052 | 1,186 | 839.44 | 970.8 | 1,185 |
Capital Expenditures CapEx Growth | -1,008 | -974.1 | -624.81 | -671 | -598.96 | -482.5 |
Free Cash Flow Free Cash Flow Growth | 85.72 | 78.34 | 561.45 | 168.44 | 371.84 | 702.48 |
Free Cash Flow Growth | -71.62% | -86.05% | 233.31% | -54.70% | -47.07% | -4.01% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 74.19% | 74.61% | 71.64% | 68.34% | 71.26% | 73.47% |
Operating Margin | 13.98% | 14.71% | 17.04% | 16.81% | 16.24% | 16.49% |
Pretax Margin | 13.55% | 15.07% | 15.76% | 19.07% | 20.50% | 19.61% |
Profit Margin | 14.33% | 14.97% | 14.99% | 17.24% | 18.30% | 17.45% |
FCF Margin | 1.82% | 1.80% | 13.99% | 5.00% | 10.68% | 22.97% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.550 | 0.550 | 0.500 | 0.500 | 0.500 | 0.400 |
Dividend Per Share Growth | 10.00% | 10.00% | 0% | 0% | 25.00% | - |
Dividend Yield | 1.63% | 1.13% | 1.66% | 1.60% | 1.62% | 1.59% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 53.66 | 84.79 | 57.32 | 61.45 | 56.86 | 56.62 |
Forward PE | - | 75.65 | 51.55 | 58.32 | 54.75 | 27.88 |
P/FCF Ratio | 416.07 | 705.15 | 61.42 | 211.61 | 97.42 | 43.02 |
PS Ratio | 7.59 | 12.69 | 8.59 | 10.59 | 10.40 | 9.88 |